---
title: "Virax Mulls Bringing UK Biotech Startup’s Immune Profiling Platform to China, Chair Says"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285902519.md"
description: "Virax Biolabs is considering introducing its T-cell immune profiling platform for diagnosing post-acute infection syndromes, including long Covid, to China. Chairman James Foster highlighted China's dynamic healthcare market and the potential for strategic partnerships at the Shanghai Y50 Forum. Established in 2013, Virax has developed the ViraxImmune platform, currently undergoing clinical validations in the UK and preparing for the US. Foster noted the significant burden of post-acute syndromes on healthcare systems and expressed interest in localizing production in China, leveraging the country's innovative biotech environment."
datetime: "2026-05-11T08:01:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285902519.md)
  - [en](https://longbridge.com/en/news/285902519.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285902519.md)
---

# Virax Mulls Bringing UK Biotech Startup’s Immune Profiling Platform to China, Chair Says

(Yicai) May 11 -- Virax Biolabs is considering bringing its T-cell immune profiling platform for the diagnosis of post-acute infection syndromes, such as long Covid, to China to embrace the country’s huge market potential, according to the UK biotech startup’s chairman.

“China is arguably the most dynamic and one of the largest healthcare markets in the world, so we’re obviously gonna be interested in being here,” James Foster, who is also Virax’s co-founder and chief executive officer, told Yicai during the seventh Shanghai Y50 Forum for Innovation and Entrepreneurship yesterday.

Established in London in 2013, Virax has developed a T-cell immune profiling platform named ViraxImmune, which focuses on T-cell diagnostics and functional immune monitoring in post-acute infection syndromes. It has entered clinical validations in the United Kingdom and is preparing to apply for the same process in the United States.

“We’ve been told that the Y50 forum brings together innovators, ecosystems, and investors around biotech, so we wanted to come here, have a look, see where we might fit in strategically, start to talk to partners, and see from where Virax might enter the China market,” Foster noted. “It seems to be the best form to do that.”

Foster believes that post-acute infection syndromes are a really broad and underserved diagnostic category, as between 2 percent and 3 percent of the world’s population has some form of these syndromes, such as long Covid, chronic fatigue syndrome, and post-treatment Lyme, bringing a massive burden to medical service systems every year.

“We’re just starting to look at clinical validation possibilities in China,” he said, adding that his team had some early-stage conversations with potential partners and is seeking opportunities to localize production in the country.

China is trying to attract the most innovative biotechnology companies in the world with its regulatory systems and markets, Foster pointed out. Shanghai, in particular, has great strengths in innovation, capital, manufacturing, and government support, which can help small companies like Virax to expand, he noted.

The Shanghai Y50 Forum for Innovation and Entrepreneurship is an annual flagship event aiming to establish the Chinese eastern megacity as a leading global hub for young talent.

Editor: Futura Costaglione

### Related Stocks

- [VRAX.US](https://longbridge.com/en/quote/VRAX.US.md)

## Related News & Research

- [World is more vulnerable to pandemics despite Covid-19 lessons, warns WHO](https://longbridge.com/en/news/286895865.md)
- [Larimar Therapeutics Q1 net loss widens slightly R&D expenses fall](https://longbridge.com/en/news/286404964.md)
- [Nanjing Leads Biolabs Wins HKEX Approval for H-Share Full Circulation](https://longbridge.com/en/news/286430077.md)
- [Cardiff Oncology Q1 net loss narrows as operating expenses fall](https://longbridge.com/en/news/286476049.md)
- [Mereo BioPharma Shareholders Approve All AGM Resolutions](https://longbridge.com/en/news/286435474.md)